QQQ   370.55 (-2.49%)
AAPL   169.80 (-1.89%)
MSFT   302.65 (-2.43%)
FB   318.15 (-4.14%)
GOOGL   2,719.96 (-2.50%)
AMZN   3,178.35 (-1.99%)
TSLA   1,030.51 (-1.82%)
NVDA   259.03 (-3.86%)
BABA   128.60 (-2.26%)
NIO   29.61 (-4.33%)
AMD   131.93 (-3.62%)
CGC   7.78 (-7.38%)
MU   92.87 (-4.61%)
GE   102.89 (-0.26%)
T   27.31 (+0.48%)
F   24.38 (-3.22%)
DIS   152.27 (+0.22%)
AMC   18.84 (-8.41%)
PFE   54.11 (-1.53%)
ACB   5.11 (-7.26%)
BA   225.01 (-0.42%)
QQQ   370.55 (-2.49%)
AAPL   169.80 (-1.89%)
MSFT   302.65 (-2.43%)
FB   318.15 (-4.14%)
GOOGL   2,719.96 (-2.50%)
AMZN   3,178.35 (-1.99%)
TSLA   1,030.51 (-1.82%)
NVDA   259.03 (-3.86%)
BABA   128.60 (-2.26%)
NIO   29.61 (-4.33%)
AMD   131.93 (-3.62%)
CGC   7.78 (-7.38%)
MU   92.87 (-4.61%)
GE   102.89 (-0.26%)
T   27.31 (+0.48%)
F   24.38 (-3.22%)
DIS   152.27 (+0.22%)
AMC   18.84 (-8.41%)
PFE   54.11 (-1.53%)
ACB   5.11 (-7.26%)
BA   225.01 (-0.42%)
QQQ   370.55 (-2.49%)
AAPL   169.80 (-1.89%)
MSFT   302.65 (-2.43%)
FB   318.15 (-4.14%)
GOOGL   2,719.96 (-2.50%)
AMZN   3,178.35 (-1.99%)
TSLA   1,030.51 (-1.82%)
NVDA   259.03 (-3.86%)
BABA   128.60 (-2.26%)
NIO   29.61 (-4.33%)
AMD   131.93 (-3.62%)
CGC   7.78 (-7.38%)
MU   92.87 (-4.61%)
GE   102.89 (-0.26%)
T   27.31 (+0.48%)
F   24.38 (-3.22%)
DIS   152.27 (+0.22%)
AMC   18.84 (-8.41%)
PFE   54.11 (-1.53%)
ACB   5.11 (-7.26%)
BA   225.01 (-0.42%)
QQQ   370.55 (-2.49%)
AAPL   169.80 (-1.89%)
MSFT   302.65 (-2.43%)
FB   318.15 (-4.14%)
GOOGL   2,719.96 (-2.50%)
AMZN   3,178.35 (-1.99%)
TSLA   1,030.51 (-1.82%)
NVDA   259.03 (-3.86%)
BABA   128.60 (-2.26%)
NIO   29.61 (-4.33%)
AMD   131.93 (-3.62%)
CGC   7.78 (-7.38%)
MU   92.87 (-4.61%)
GE   102.89 (-0.26%)
T   27.31 (+0.48%)
F   24.38 (-3.22%)
DIS   152.27 (+0.22%)
AMC   18.84 (-8.41%)
PFE   54.11 (-1.53%)
ACB   5.11 (-7.26%)
BA   225.01 (-0.42%)
NASDAQ:LJPC

La Jolla Pharmaceutical Stock Forecast, Price & News

$4.57
-0.35 (-7.11%)
(As of 01/18/2022 12:00 AM ET)
Add
Compare
Today's Range
$4.54
▼
$4.96
50-Day Range
$3.59
▼
$4.92
52-Week Range
$3.35
▼
$7.85
Volume
95,973 shs
Average Volume
111,366 shs
Market Capitalization
$125.78 million
P/E Ratio
14.28
Dividend Yield
N/A
Beta
2.29
View Price History Chart DataSkip Price History Chart
30 days | 90 days | 365 days | Advanced Chart
Receive LJPC News and Ratings via Email

Sign-up to receive the latest news and ratings for La Jolla Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.


La Jolla Pharmaceutical logo

About La Jolla Pharmaceutical

La Jolla Pharmaceutical Co. operates as a biopharmaceutical company. It engages in the discovery, development and commercialization of therapies intended to improve outcomes in patients suffering from life-threatening diseases. Its products portfolio include GIAPREZA and XERAVA. The company was founded in 1989 and is headquartered in San Diego, CA.

Headlines

La Jolla Pharmaceutical Company Common Stock (DE) (LJPC)
January 13, 2022 |  nasdaq.com
La Jolla Pharmaceutical (NASDAQ:LJPC) Shares Pass Above 50 Day Moving Average of $4.36
January 13, 2022 |  americanbankingnews.com
La Jolla Pharmaceutical Company Announces Share Repurchase Plan
November 17, 2021 |  finance.yahoo.com
Shareholders in La Jolla Pharmaceutical (NASDAQ:LJPC) are in the red if they invested five years ago
November 8, 2021 |  nasdaq.com
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Nine Months Ended September 30, 2021 and Highlights Corporate Progress
November 4, 2021 |  finance.yahoo.com
La Jolla Pharmaceutical (LJPC) Reports Q3 Loss, Tops Revenue Estimates
November 4, 2021 |  finance.yahoo.com
La Jolla Pharmaceutical (LJPC) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
November 1, 2021 |  finance.yahoo.com
La Jolla Pharmaceutical (NASDAQ:LJPC) shareholders have endured a 79% loss from investing in the stock five years ago
October 25, 2021 |  finance.yahoo.com
Kidney Fibrosis Treatment Market Growth Predictions, Top Manufacturers, Regional Segmentation, Business Strategy and Demand Status by 2026
September 24, 2021 |  marketwatch.com
La Jolla Pharmaceutical (LJPC) Tops Q2 Earnings and Revenue Estimates
August 5, 2021 |  finance.yahoo.com
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Six Months Ended June 30, 2021 and Highlights Corporate Progress
August 5, 2021 |  finance.yahoo.com
Will La Jolla Pharmaceutical (LJPC) Report Negative Q2 Earnings? What You Should Know
July 29, 2021 |  finance.yahoo.com
La Jolla Pharmaceutical Company (NASDAQ:LJPC) Has Found A Path To Profitability
July 26, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LJPC
Previous Symbol
CUSIP
N/A
CIK
920465
Web
www.lajollapharmaceutical.com
Phone
(617) 715-3600
Fax
858-626-2851
Employees
59
Year Founded
N/A

Sales & Book Value

Annual Sales
$33.42 million
Price / Sales
3.76
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($3.36) per share
Price / Book
-1.36

Profitability

EPS (Most Recent Fiscal Year)
$0.32
Net Income
$-39.42 million
Net Margins
16.67%
Pretax Margin
16.74%
Return on Equity
-15.92%
Return on Assets
13.71%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.12
Quick Ratio
3.74

Price-To-Earnings

Trailing P/E Ratio
14.28
Forward P/E Ratio
8.62
P/E Growth
N/A

Miscellaneous

Outstanding Shares
27,524,000
Free Float
17,533,000
Market Cap
$125.78 million
Optionable
Optionable

Company Calendar

Last Earnings
11/04/2021
Today
1/18/2022
Next Earnings (Estimated)
3/14/2022
Fiscal Year End
12/31/2022

MarketRank™

Overall MarketRank™

2.52 out of 5 stars

Medical Sector

121st out of 1,414 stocks

Biological Products, Except Diagnostic Industry

20th out of 206 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 1.3 5 -4 -3 -2 -1 -












La Jolla Pharmaceutical (NASDAQ:LJPC) Frequently Asked Questions

Is La Jolla Pharmaceutical a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for La Jolla Pharmaceutical in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" La Jolla Pharmaceutical stock.
View analyst ratings for La Jolla Pharmaceutical or view top-rated stocks.

How has La Jolla Pharmaceutical's stock been impacted by COVID-19 (Coronavirus)?

La Jolla Pharmaceutical's stock was trading at $4.81 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, LJPC stock has decreased by 5.0% and is now trading at $4.57.
View which stocks have been most impacted by COVID-19.

Are investors shorting La Jolla Pharmaceutical?

La Jolla Pharmaceutical saw a increase in short interest in the month of December. As of December 31st, there was short interest totaling 681,300 shares, an increase of 59.9% from the December 15th total of 426,200 shares. Based on an average trading volume of 123,900 shares, the days-to-cover ratio is currently 5.5 days. Approximately 2.5% of the company's shares are short sold.
View La Jolla Pharmaceutical's Short Interest.

When is La Jolla Pharmaceutical's next earnings date?

La Jolla Pharmaceutical is scheduled to release its next quarterly earnings announcement on Monday, March 14th 2022.
View our earnings forecast for La Jolla Pharmaceutical.

How were La Jolla Pharmaceutical's earnings last quarter?

La Jolla Pharmaceutical (NASDAQ:LJPC) issued its earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($0.08) EPS for the quarter, missing the Zacks' consensus estimate of ($0.07) by $0.01. The biopharmaceutical company had revenue of $13.31 million for the quarter, compared to the consensus estimate of $12.10 million. La Jolla Pharmaceutical had a net margin of 16.67% and a negative trailing twelve-month return on equity of 15.92%.
View La Jolla Pharmaceutical's earnings history.

What price target have analysts set for LJPC?

1 brokers have issued 1 year price objectives for La Jolla Pharmaceutical's stock. Their forecasts range from $15.00 to $15.00. On average, they expect La Jolla Pharmaceutical's share price to reach $15.00 in the next twelve months. This suggests a possible upside of 228.2% from the stock's current price.
View analysts' price targets for La Jolla Pharmaceutical or view top-rated stocks among Wall Street analysts.

Who are La Jolla Pharmaceutical's key executives?

La Jolla Pharmaceutical's management team includes the following people:
  • Larry G. Edwards, President, Chief Executive Officer & Director
  • Luke Seikkula, Senior Vice President-Pharmaceutical Operations
  • Michael S. Hearne, Chief Financial Officer & Secretary
  • Tony Hodges, Chief Medical Officer
  • Stewart M. Kroll, Chief Development Officer

What is George F. Tidmarsh's approval rating as La Jolla Pharmaceutical's CEO?

8 employees have rated La Jolla Pharmaceutical CEO George F. Tidmarsh on Glassdoor.com. George F. Tidmarsh has an approval rating of 49% among La Jolla Pharmaceutical's employees. This puts George F. Tidmarsh in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of La Jolla Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other La Jolla Pharmaceutical investors own include BioCryst Pharmaceuticals (BCRX), Intercept Pharmaceuticals (ICPT), Exelixis (EXEL), Neurocrine Biosciences (NBIX), Advanced Micro Devices (AMD), El Pollo Loco (LOCO), Sarepta Therapeutics (SRPT), Inovio Pharmaceuticals (INO), NVIDIA (NVDA) and XOMA (XOMA).

What is La Jolla Pharmaceutical's stock symbol?

La Jolla Pharmaceutical trades on the NASDAQ under the ticker symbol "LJPC."

Who are La Jolla Pharmaceutical's major shareholders?

La Jolla Pharmaceutical's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include HealthInvest Partners AB (3.02%) and Hollencrest Capital Management (0.30%). Company insiders that own La Jolla Pharmaceutical stock include David A Ramsay and Kevin C Tang.
View institutional ownership trends for La Jolla Pharmaceutical.

Which major investors are buying La Jolla Pharmaceutical stock?

LJPC stock was purchased by a variety of institutional investors in the last quarter, including HealthInvest Partners AB, and Hollencrest Capital Management. Company insiders that have bought La Jolla Pharmaceutical stock in the last two years include David A Ramsay, and Kevin C Tang.
View insider buying and selling activity for La Jolla Pharmaceutical or or view top insider-buying stocks.

How do I buy shares of La Jolla Pharmaceutical?

Shares of LJPC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is La Jolla Pharmaceutical's stock price today?

One share of LJPC stock can currently be purchased for approximately $4.57.

How much money does La Jolla Pharmaceutical make?

La Jolla Pharmaceutical has a market capitalization of $125.78 million and generates $33.42 million in revenue each year. The biopharmaceutical company earns $-39.42 million in net income (profit) each year or $0.32 on an earnings per share basis.

How many employees does La Jolla Pharmaceutical have?

La Jolla Pharmaceutical employs 59 workers across the globe.

What is La Jolla Pharmaceutical's official website?

The official website for La Jolla Pharmaceutical is www.lajollapharmaceutical.com.

Where are La Jolla Pharmaceutical's headquarters?

La Jolla Pharmaceutical is headquartered at 4550 TOWNE CENTRE COURT, SAN DIEGO CA, 92121.

How can I contact La Jolla Pharmaceutical?

La Jolla Pharmaceutical's mailing address is 4550 TOWNE CENTRE COURT, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at (617) 715-3600, via email at [email protected], or via fax at 858-626-2851.


This page was last updated on 1/18/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.